CONTRACT NOTICE – NATIONAL

1 Authority Details

1.1

Authority Name and Address

1.2

Address from which documentation may be obtained

1.3

Completed documents must be returned to:

2 Contract Details

2.1

Title

Provision of ‘Methods of identifying economic evaluations of durability and treatment response

2.2

Description of the goods or services required

The Welsh Government has committed to develop an All-Wales Cell and Gene Therapy Strategy and has commissioned the Welsh Blood Service (as part of the Velindre NHS Trust) to support the development of this work. The programme launched in 2018, with the key objectives of the strategy being:

• Implement & secure healthcare value & patient benefit

• Support development of skilled workforce

• Increase research in Wales (Inc. clinical trials)

• Support increased innovation > commercialisation of products & services

• Accelerate adoption of new technology

• Support economic development, business growth & job creation

• Position Wales as key partner in UK-International collaborative work

The requirement is for a consultant / consultancy to work on behalf of the Welsh Blood Service within the MW-ATTC programme to develop the work as described below for a period of 4 months, starting from March 2021 through to and including June 2021 for the completion of Phase 1 (Phase 1 not exceeding 50% of total project costs and with the option to extend into Phases 2 ,3 and 4 for further 7 months) in order to support the identification of methods for deriving plausible assumptions of durability of treatment response and evidence that value attributes linked to ATMPs are deemed rewardable by society and to develop / establish a White Paper(s) on the ‘Methods of Identifying Economic Evaluation of Durability and Treatment Response’ and ‘Value attributes linked to ATMPs are deemed rewardable by society’.

NOTE: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at https://www.sell2wales.gov.wales/search/search_switch.aspx?ID=107450

2.3

Notice Coding and Classification

2.4

Total quantity or scope of tender

The supplier will be required to supply guidance / advisory services with appropriate expert knowledge and skills to undertake the tasks required;

• Undertake a systematic review of literature concerning opinion-based and statistical approaches will be reviewed and appraised for suitability as evidence, interim to the maturation of clinical and economic data to identify a range of potential methods that will be reviewed for their appropriateness in deriving ‘priors’ for the clinical efficacy of medical interventions

• Conduct a comprehensive review of existing evidence for differential valuation of benefit attributes.

• Consider the attributes that map against the reported benefits of currently authorised ATMPs, and project the implications of preferential weighting (or application of modifiers) to health technology appraisal.

• Production of a White Papers on the ‘Methods of Identifying Economic Evaluation of Durability and Treatment Response’ and ‘Value attributes linked to ATMPs are deemed rewardable by society’.

3 Conditions for Participation

3.1

Minimum standards and qualification required

- advanced qualification in Health Economics

- advanced knowledge and understanding of molecular and clinical pharmacology

- extensive knowledge of Health Technology Assessment reporting

- knowledge and experience of Cell and Gene Therapy.

4 Administrative Information

4.1

Type of Procedure

Single stage

4.2

Reference number attributed to the notice by the contracting authority

WBS-ITT-46342

4.3

Time Limits

4.5

Language or languages in which tenders or requests to participate can be drawn up

4.6

Tender Submission Postbox

5 Other Information

5.1

Additional Information

(WA Ref:107450)

5.2

Additional Documentation

5.3

Publication date of this notice